THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...
Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug. The device, created in conjunction with ...
Amgen (NASDAQ: AMGN) today announced that the Company will discuss the data supporting the Repatha TM (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results